Advances and short comings in the early diagnosis of melanoma

Melanoma Research

Volumn 20, Issue 6, 2010, Pages 450-458

  Divito, Sherrie J ^a   Ferris, Laura Korb ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

dermatoscopy; detection; imaging; melanoma; screening; skin examination

Indexed keywords

5 CYSTEINYLDOPA; COMPLEMENTARY DNA; DNA; GLYPICAN 3; KERATIN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; OSTEONECTIN; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EXAMINATION; CONFOCAL LASER MICROSCOPY; CYTOMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOG; EARLY DIAGNOSIS; ELECTROCHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILUMINESCENCE MICROSCOPY; HUMAN; IMAGING SYSTEM; IMPEDANCE SPECTROSCOPY; INTERFEROMETER; MEDICAL PHOTOGRAPHY; MEDICAL TECHNOLOGY; MELANOMA; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHYSICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REFLEX TRANSMISSION IMAGING; REVIEW; SELF EXAMINATION; SKIN BIOPSY; SKIN CANCER; SMELLING; SPECTROSCOPY; X RAY ANALYSIS; X RAY FIBER DIFFRACTION;

ANIMALS; DOGS; EARLY DIAGNOSIS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 78349313474     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833faf7e     Document Type: Review

References (133)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol1990; 23:308-310.
3. Balch CM, Gershenwald JE, Soong SJ,Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
4. Brady MS, Oliveria SA, Christos PJ, Berwick M, Coit DG, Katz J, et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000; 89:342-347.
5. Kantor J, Kantor DE. Routine dermatologist-performed full-body skin examination and early melanoma detection. Arch Dermatol 2009; 145:873-876.
6. Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE. Is physician detection associated with thinner melanomas? JAMA 1999; 281:640-643.
7. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self examination of the skin. CA Cancer J Clin 1985; 35:130-151.
8. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004; 292:2771-2776.
9. Rigel DS, Friedman RJ, Kopf AW, Polsky D. ABCDE-an evolving concept in the early detection of melanoma. Arch Dermatol 2005; 141:1032-1034.
10. Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch Dermatol 2001; 137:1583-1589.
11. Kittler H, Guitera P, Riedl E, Avramidis M, Teban L, Fiebiger M, et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch Dermatol 2006; 142:1113-1119.
12. Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch Dermatol 2008; 144: 502-506.
13. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol 2000; 42:731-734.
14. Carli P, Massi D, de Giorgi V, Giannotti B. Clinically and dermoscopically featureless melanoma: when prevention fails. JAm Acad Dermatol 2002; 46:957-959.
15. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007; 57:555-572.
16. Scope A, Dusza SW, Halpern AC, Rabinovitz H, Braun RP, Zalaudek I, et al. The ugly duckling sign: agreement between observers. Arch Dermatol 2008; 144:58-64.
17. Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C, et al. Dermatologist detection and skin self examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607-612.
18. Pollitt RA, Geller AC, Brooks DR, Johnson TM, Park ER, Swetter SM. Efficacy of skin self-examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009; 18:3018-3023.
19. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self examination. J Natl Cancer Inst 1996; 88:17-23.
20. Muhn CY, From L, Glied M. Detection of artificial changes in mole size by skin self-examination. J Am Acad Dermatol 2000; 42:754-759.
21. Weinstock MA, Martin RA, Risica PM, Berwick M, Lasater T, Rakowski W, et al. Thorough skin examination for the early detection of melanoma. Am J Prev Med 1999; 17:169-175.
22. Fisher NM, Schaffer JV, Berwick M, Bolognia JL. Breslow depth of cutaneous melanoma: impact offactors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005; 53:393-406.
23. Oliveria SA, Christos PJ, Marghoob AA, Halpern AC Skin cancer screening and prevention in the primary care setting: national ambulatory medical care survey 1997. J Gen Intern Med 2001; 16:297-301.
24. Berg AO; US Preventive Services Task Force. Screening for skin cancer: Recommendations and rationale. Am J Prev Med 2001; 20: 44-46.
25. Ferrini RL, Perlman M, Hill L. American College of Preventive Medicine policy statement: screening for skin cancer. Am J Prev Med 1998; 14:80-82.
26. McDonald CJ. American Cancer Society perspective on the American College of Preventive Medicine's policy statements on skin cancer prevention and screening. CA Cancer J Clin 1998; 48:229-231.
27. Gynecologists ACoOa. Committee Opinion No. 356: Routine Cancer Screening. Obstet Gynecol 2006; 108:1611-1614.
28. Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: a survey of Fellows of the American Academy of Dermatology. J Am Acad Dermatol 2002; 46:674-682.
29. Brochez L, Verhaeghe E, Bleyen L, Naeyaert JM. Diagnostic ability of general practitioners and dermatologists in discriminating pigmented skin lesions. J Am Acad Dermatol 2001; 44:979-986.
30. Friedman RJ, Gutkowicz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, et al. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008; 144:476-482.
31. Chen SC, Bravata DM, Weil E, Olkin I. A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. Arch Dermatol 2001; 137:1627-1634.
32. Chen SC, Pennie ML, Kolm P, Warshaw EM, Weisberg EL, Brown KM, et al. Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med 2006; 21:678-682.
33. English DR, Burton RC, del Mar CB, Donovan RJ, Ireland PD, Emery G. Evaluation of aid to diagnosis of pigmented skin lesions in general practice: controlled trial randomised by practice. Br Med J 2003; 327:375.
34. Carli P, Nardini P, Crocetti E, De Giorgi V, Giannotti B. Frequency and characteristics of melanomas missed at a pigmented lesion clinic: a registry-based study. Melanoma Res 2004; 14:403-407.
35. Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol 2007; 143:488-494.
36. Veronesi A, Pizzichetta MA, De Giacomi C, Gatti A,Trevisan G. A two-year regional program for the early detection of cutaneous melanoma. Tumori 2003; 89:1-5.
37. Katris P, Donovan RJ, Gray BN. Nurses screening for skin cancer: an observation study. Aust N Z J Public Health 1998; 22:381-383.
38. Medicine Io. Extending Medicare coverage for prevention and other services. In: Field MJ, Lawrence RL, Zwanziger L, editors. Screening for skin cancer. Washington, DC: National Academy Press; 2000.
39. MacKie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Br Med J 1996; 312:1125-1128.
40. Lasithiotakis KG, Petrakis IE, Garbe C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 2010;20:163-170.
41. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55:490-500.
42. Losina E, Walensky RP, Geller A, Beddingfield FC III, Wolf LL, Gilchrest BA, et al. Visual screening for malignant melanoma: a cost effectiveness analysis. Arch Dermatol 2007; 143:21-28.
43. Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: A cost-effectiveness analysis. J Am Acad Dermatol 1999; 41:738-745.
44. Burton RC, Howe C, Adamson L, Reid AL, Hersey P, Watson A, et al. General practitioner screening for melanoma: sensitivity, specificity, and effect of training. J Med Screen 1998; 5:156-161.
45. Rigel DS. Is the ounce of screening and prevention for skin cancer worth the pound ofcure? CA Cancer J Clin 1998; 48:236-238.
46. Bono A, Maurichi A, Moglia D, Camerini T, Tragni G, Lualdi M, et al. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. Melanoma Res 2001; 11:491-494.
47. Pizzichetta MA,Talamini R, Stanganelli I, Puddu P, Bono R, Argenziano G, et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol 2004; 150:1117-1124.
48. Zalaudek I, Docimo G, Argenziano G. Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol 2009; 145:816-826.
49. De Troya-Martin M, Blazquez-Sanchez N, Fernandez-Canedo I, Frieyro-Elicegui M, Funez-Liebana R, Rivas-Ruiz F. Dermoscopic study of cutaneous malignant melanoma: descriptive analysis of 45 cases. Actas Dermosifiliogr 2008; 99:44-53.
50. Carli P, de Giorgi V, Chiarugi A, Nardini P,Weinstock MA, Crocetti E, et al. Addition of dermoscopy to conventional naked eye examination in melanoma screening: a randomized study. J Am Acad Dermatol 2004; 50:683-689.
51. Carli P, De Giorgi V, Crocetti E, Mannone F, Massi D, Chiarugi A, et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001. Br J Dermatol 2004; 150:687-692.
52. Stanganelli I, Serafini M, Bucch L. A cancer registry-assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented skin lesions. Dermatology 2000; 200:11-16.
53. Piccolo D, Ferrari A, Peris K, Diadone R, Ruggeri B, Chimenti S. Dermoscopic diagnosis by a trained clinician versus a clinician with minimal dermoscopy training versus computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. Br J Dermatol 2002; 147:481-486.
54. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3:159-165.
55. Goodson AG, Grossman D. Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol 2009; 60:719-735.
56. Braun RP, Rabinovitz H, Tzu JE, Marghoob AA. Dermoscopy research-an update. Semin Cutan Med Surg 2009; 28:165-171.
57. Braun RP, Gaide O, Skaria AM, Kopf AW, Saurat JH, Marghoob AA. Exclusively benign dermoscopic pattern in a patient with acral melanoma. Arch Dermatol 2007; 143:1213-1215.
58. Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch Dermatol 2005; 141:155-160.
59. Noor O II, Nanda A, Rao BK. A dermoscopy survey to assess who is using it and why it is or is not being used. Int J Dermatol 2009; 48:951-952.
60. Haenssle HA, Krueger U, Vente C, Thoms KM, Bertsch HP, Zutt M, et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol2006; 126:980-985.
61. Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J Dermatol 2009; 161:1270-1277.
62. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust 1997; 167:191-194.
63. Lucas CR, Sanders LL, Murray JC, Myers SA, Hall RP, Grichnik JM. Early melanoma detection: nonuniform dermoscopic features and growth. J Am Acad Dermatol 2003; 48:663-671.
64. Marks R, Dorevitch AP, Mason G. Do all melanomas come from moles? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol1990; 31:77-80.
65. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139:1620-1624.
66. Halpern AC, Marghoob AA, Bialoglow TW, Witmer W, Slue W. Standardized positioning of patients (poses) for whole body cutaneous photography. J Am Acad Dermatol 2003; 49:593-598.
67. Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141:998-1006.
68. Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 2004; 150:706-714.
69. Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur AF, Heilman ER, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989; 63:386-389.
70. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993; 341:1618-1620.
71. Oliveria SA, Chau D, Christos PJ, Charles CA, Mushlin AI, Halpern AC Diagnostic accuracy of patients in performing skin self examination and the impact of photography. Arch Dermatol 2004; 140:57-62.
72. Risser J, Pressley Z, Veledar E, Washington C, Chen SC. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol 2007; 57:428-434.
73. Rajadhyaksha M, Gonzalez S, Zavislan JM, Anderson RR, Webb RH. In vivo confocal scanning laser microscopy of human skin II: advances in instrumentation and comparison with histology. J Invest Dermatol1999; 113:293-303.
74. Scope A, Benvenuto-Andrade C, Agero AL, Halpern AC, Gonzalez S, Marghoob AA. Correlation of dermoscopic structures of melanocytic lesions to reflectance confocal microscopy. Arch Dermatol 2007; 143:176-185. (Pubitemid 46294583)
75. Ahlgrimm-Siess V, Massone C, Koller S, Fink-Puches R, Richtig E, Wolf I, et al. In vivo confocal scanning laser microscopy of common naevi with globular, homogeneous and reticular pattern in dermoscopy. Br J Dermatol2008; 158:1000-1007.
76. Tannous ZS, Mihm MC, Flotte TJ, Gonzalez S. In vivo examination of lentigo maligna and malignant melanoma in situ, lentigo maligna type by near-infrared reflectance confocal microscopy: comparison of in vivo confocal images with histologic sections. J Am Acad Dermatol 2002; 46:260-263.
77. Pellacani G, Cesinaro AM, Seidenari S. In vivo assessment of melanocytic nests in nevi and melanomas by reflectance confocal microscopy. Mod Pathol 2005; 18:469-474.
78. Rajadhyaksha M, Gonzalez S, Zavislan JM. Detectability of contrast agents for confocal reflectance imaging of skin and microcirculation. J Biomed Opt 2004; 9:323-331.
79. Busam KJ, Charles C, Lohmann CM, Marghoob A, Goldgeier M, Halpern AC Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy. Melanoma Res 2002; 12:349-355.
80. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. J Invest Dermatol 1995; 104:946-952.
81. Gerger A, Koller S, Weger W, Richtig E, Kerl H, Samonigg H, et al. Sensitivity and specificity of confocal laser-scanning microscopy for in vivo diagnosis of malignant skin tumors. Cancer 2006; 107:193-200.
82. Gerger A, Hofmann-Wellenhof R, Langsenlehner U, Richtig E, Koller S, Weger W, et al. In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images. Br J Dermatol 2008; 158:329-333.
83. Aghassi D, Anderson RR, Gonzalez S. Time-sequence histologic imaging of laser-treated cherry angiomas with in vivo confocal microscopy. J Am Acad Dermatol 2000; 43:37-41.
84. Gonzalez S, Gilaberte-Calzada Y. In vivo reflectance-mode confocal microscopy in clinical dermatology and cosmetology. Int J Cosmet Sci 2008; 30:1-17.
85. Moncrieff M, Cotton S, Claridge E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. Br J Dermatol 2002; 146:448-457.
86. Govindan K, Smith J, Knowles L, Harvey A, Townsend P, Kenealy J. Assessment of nurse-led screening of pigmented lesions using SIAscope. J Plast Reconstr Aesthet Surg 2007; 60:639-645.
87. Haniffa MA, Lloyd JJ, Lawrence CM. The use of a spectrophotometric intracutaneous analysis device in the real-time diagnosis of melanoma in the setting of a melanoma screening clinic. Br J Dermatol 2007; 156:1350-1352.
88. Monheit G, Cognetta A, Gutkowicz-Krusin D, Ferris LK. Prospective multicenter study of an objective computer-vision system for early melanoma detection. J Am Acad Dermatol 2010; 62:AB7.
89. De Giorgi V, Stante M, Massi D, Mavilia L, Cappugi P, Carli P. Possible histopathologic correlates of dermoscopic features in pigmented melanocytic lesions identified by means of optical coherence tomography. Exp Dermatol 2005; 14:56-59.
90. Vogt M, Knuttel A, Hoffmann K, Altmeyer P, Ermert H. Comparison of high frequency ultrasound and optical coherence tomography as modalities for high resolution and non invasive skin imaging. Biomed Tech (Berl) 2003; 48:116-121.
91. Rallan D, Dickson M, Bush NL, Harland CC, Mortimer P, Bamber JC. High-resolution ultrasound reflex transmission imaging and digital photography: potential tools for the quantitative assessment of pigmented lesions. Skin Res Technol 2006; 12:50-59.
92. Rallan D, Bush NL, Bamber JC, Harland CC. Quantitative discrimination of pigmented lesions using three-dimensional high-resolution ultrasound reflex transmission imaging. J Invest Dermatol 2007; 127:189-195.
93. Wong R, Tran V, Morhenn V, Hung SP, Andersen B, Ito E, et al. Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inflamed skin. J Invest Dermatol 2004; 123:159-167.
94. Benson NR, Papenfuss J, Wong R, Motaal A, Tran V, Panko J, et al. An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. J Invest Dermatol 2006; 126:2234-2241.
95. Wachsman W, Zapala M, Udall D, Paik A, Hata T, Walls L, et al. Differentiation of melanoma from dysplastic nevi in suspicious pigmented skin lesions by non-invasive tape stripping. J Invest Dermatol 2007; 127:S145.
96. Wachsman W, Hata T, Walls L, Palmer T, Bastian B, Lu X, et al. Development of a multi-gene classifier to determine the risk of melanoma in suspicious pigmented nevi by non-invasive tape stripping. J Invest Dermatol2008; 128:S213.
97. Wachsman W, Walls L, Palmer T, Chang S. Development of a non-invasive genomic-based assay to detect melanoma. J Invest Dermatol 2009; 129:S141.
98. Bocking A, Adler CP, Common HH, Hilgarth M, Granzen B, Auffermann W. Algorithm for a DNA-cytophotometric diagnosis and grading of malignancy. Anal Quant Cytol1984; 6:1-8.
99. Weger AR, Glaser KS, Schwab G, Oefner D, Bodner E, Auer GU, et al. Quantitative nuclear DNA content in fine needle aspirates of pancreatic cancer. Gut 1991; 32:325-328.
100. Bauer HC, Kreicbergs A, Silfversward C,Tribukait B. DNA analysis in the differential diagnosis of osteosarcoma. Cancer 1988; 61:2532-2540.
101. Buchner T, Hiddemann W, Wormann B, Kleinemeier B, Schumann J, Gohde W, et al. Differential pattern of DNA-aneuploidy in human malignancies. Pathol Res Pract 1985; 179:310-317.
102. Sondergaard K, Larsen JK, Moller U, Christensen IJ, Hou-Jensen K. DNA ploidy-characteristics of human malignant melanoma analysed by flow cytometry and compared with histology and clinical course. Virchows Arch B Cell Pathol Incl Mol Pathol1983; 42:43-52.
103. Satoh S, Hashimoto-Tamaoki T, Furuyama J, Mihara K, Namba M, Kitano Y. High frequency oftetraploidy detected in malignant melanoma ofJapanese patients by fluorescence in situ hybridization. Int J Oncol 2000; 17:707-715.
104. Steinbeck ZR, Heselmeyer KM, Gerlach B, Bjornhagen V, Auer GU. Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions. Melanoma Res 1996; 6:37-43.
105. Alvarez-Mendoza A, Reyes-Esparza J, Ruiz-Maldonado R, Lopez-Corella E, Juarez-Herrera NC. Malignant melanoma in children and congenital melanocytic nevi: DNA content and cell cycle analysis by flow cytometry. Pediatr Dev Pathol 2001; 4:73-81.
106. Skowronek J, Adamska K, Filipiak K, Karas Z, Krenz RM, Rutkowski R, et al. DNA ploidy in malignant melanoma, skin cancer and pigmented nevi. Neoplasma 1997; 44:282-288.
107. Von Roenn JH, Kheir SM, Wolter JM, Coon JS. Significance of DNA abnormalities in primary malignant melanoma and nevi, a retrospective flow cytometric study. Cancer Res 1986; 46:3192-3195.
108. Sangueza OP, Hyder DM, White CR Jr, Pallander J, Perkins M, Remple N, et al. Comparison of image analysis with flow cytometry for DNA content analysis in pigmented lesions of the skin. Anal Quant Cytol Histol1992; 14:55-59.
109. Sangueza OP, Hyder DM, Bakke AC, White CR Jr. DNA determination in dysplastic nevi. A comparative study between flow cytometry and image analysis. Am J Dermatopathol 1993; 15:99-105.
110. Pilch H, Gunzel S, Schaffer U, Tanner B, Heine M. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging. Cancer2000; 88:1370-1377.
111. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004; 10:6612-6621.
112. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol1997; 108:210-214.
113. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3:171-176.
114. Ikuta Y, Nakatsura T, Kageshita T, Fukushima S, Ito S, Wakamatsu K, et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005; 11:8079-8088.
115. Ito S, Wakamatsu K, Ozeki H. Chemical analysis of melanins and its application to the study of the regulation of melanogenesis. Pigment Cell Res 2000; 13 (Suppl 8):103-109.
116. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73:629-636.
117. Karnell R, Kagedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000; 10:363-369.
118. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanomaduring immunochemotherapy. Cancer Res 1997; 57: 5073-5076.
119. Meyer T, Hauschild A, Kromminga A, Hartleb J, Arndt R, Christophers E, et al. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma. Melanoma Res 2002; 12:471-477.
120. Wakamatsu K, Yokochi M, Naito A, Kageshita T, Ito S. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients. Melanoma Res 2003; 13:357-363.
121. Astbury Wa SA. X-ray studies of the structures of hair, wool and related fibers. I. General. Trans R Soc Lond 1931; 230:75-101.
122. James VJ. Fibre diffraction from a single hair can provide an early non-invasive test for colon cancer. Med Sci Monit 2003; 9:MT79-MT84.
123. J Ames V, Kearsley J, Irving T, Amemiya Y, Cookson D. Using hair to screen for breast cancer. Nature 1999; 398:33-34.
124. J Ames VJ. A place for fiber diffraction in the detection of breast cancer? Cancer Detect Prev 2006; 30:233-238.
125. J Ames VJ. Fiber diffraction of skin and nails provides an accurate diagnosis of malignancies. Int J Cancer2009; 125:133-138.
126. Cone CD Jr. The role of the surface electrical transmembrane potential in normal and malignant mitogenesis. Ann NY Acad Sci 1974; 238:420-435.
127. Han A, Yang L, Frazier AB. Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy. Clin Cancer Res 2007; 13:139-143.
128. Alqabandi JA, Abdel-Motal UM, Youcef-Toumi K. Extracting cancer cell line electrochemical parameters at the single cell level using a microfabricated device. Biotechnol J 2009; 4:216-223.
129. Har-Shai Y, Glickman YA, Siller G, McLeod R, Topaz M, Howe C, et al. Electrical impedance scanning for melanoma diagnosis: a validation study. Plast Reconstr Surg 2005; 116:782-790.
130. Williams H, Pembroke A. Sniffer dogs in the melanoma clinic? Lancet 1989; 1:734.
131. Church J, Williams H. Another sniffer dog for the clinic? Lancet 2001; 358:930.
132. Gordon RT, Schatz CB, Myers LJ, Kosty M, Gonczy C, Kroener J, et al. The use of canines in the detection of human cancers. J Altern Complement Med2008; 14:61-67.
133. McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early-and late-stage lung and breast cancers. Integr Cancer Ther 2006; 5:30-39.